Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint® and BluePrint® in Individualizing Treatment for Breast Cancer Patients

Long-term follow-up of early-stage breast cancer patients shows significant difference in how gene expression-based tests classify patients for adjuvant chemotherapy treatment, finds MammaPrint® the best predictor of distant cancer recurrence MINT trial confirms stratification of patients classified by MammaPrint as … Continued